Ingalls & Snyder LLC lifted its holdings in Celgene Co. (NASDAQ:CELG) by 3.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 135,260 shares of the biopharmaceutical company’s stock after purchasing an additional 4,862 shares during the quarter. Ingalls & Snyder LLC’s holdings in Celgene were worth $12,760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of the company. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in Celgene by 36.9% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 342,301 shares of the biopharmaceutical company’s stock valued at $21,938,000 after acquiring an additional 92,209 shares during the last quarter. Tibra Equities Europe Ltd bought a new stake in Celgene during the first quarter valued at about $6,396,000. Bell Asset Management Ltd grew its holdings in Celgene by 13.7% during the fourth quarter. Bell Asset Management Ltd now owns 78,822 shares of the biopharmaceutical company’s stock valued at $5,052,000 after purchasing an additional 9,525 shares during the period. Global Trust Asset Management LLC grew its holdings in Celgene by 212.3% during the first quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 3,098 shares during the period. Finally, Morgan Stanley grew its holdings in Celgene by 20.4% during the third quarter. Morgan Stanley now owns 3,236,323 shares of the biopharmaceutical company’s stock valued at $289,620,000 after purchasing an additional 549,404 shares during the period. Hedge funds and other institutional investors own 74.27% of the company’s stock.
In related news, Director Ernest Mario acquired 2,000 shares of the firm’s stock in a transaction on Tuesday, February 12th. The shares were acquired at an average cost of $89.99 per share, for a total transaction of $179,980.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James J. Loughlin sold 23,466 shares of the company’s stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total value of $2,048,347.14. Following the sale, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.10. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The company had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.01 billion. During the same period in the prior year, the company earned $2.05 earnings per share. The firm’s revenue was up 13.8% on a year-over-year basis. As a group, equities research analysts forecast that Celgene Co. will post 9.85 earnings per share for the current fiscal year.
Several analysts have issued reports on CELG shares. ValuEngine raised Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. Robert W. Baird raised Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Friday, January 4th. Zacks Investment Research raised Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 price target for the company in a report on Wednesday, January 23rd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $100.00 price target on shares of Celgene in a report on Thursday, January 31st. Twenty investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Celgene presently has a consensus rating of “Hold” and an average price target of $99.13.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What is channel trading?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.